CXCR2 and neoplasm: Significantly, the treatment of orthotopic Pdxcre, LSL-KrasG12D, and Setd2f/f (KSC) tumors, with a CXCR2 antagonist reduced tumor-infiltrating neutrophiles, but had much less of an effect on tumor-infiltrating macrophages and monocytes [65].